Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.42 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.42 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.42 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27898182 | 0.97 | LMNA (0.53) | LMNAMAPTNPC1NOTUMIDO1 | |
| SCHEMBL8499115 | 0.83 | CYP2D6 (0.53) | LMNAMAPTNPC1NOTUMIDO1 | |
| SCHEMBL169510 | 0.81 | KDM4E (0.62) | LMNAMAPTNPC1NOTUMCYP19A1 | |
| SCHEMBL29395111 | 0.81 | KDM4E (0.62) | LMNAMAPTNPC1NOTUMCYP19A1 | |
| SCHEMBL10324727 | 0.81 | LMNA (0.55) | LMNAMAPTNOTUMIDO1PABPC1 | |
| SCHEMBL30578383 | 0.79 | KDM4E (0.59) | LMNAMAPTNPC1NOTUMCYP19A1 | |
| SCHEMBL8501004 | 0.79 | NPC1 (0.70) | LMNAMAPTNPC1IDO1CYP19A1 | |
| Hydrochloric Acid SCHEMBL20547526 | 0.79 | KDM4E (0.59) | LMNAMAPTNPC1NOTUMCYP19A1 | |
| SCHEMBL9120067 | 0.79 | KDM4E (0.59) | LMNAMAPTNPC1NOTUMCYP19A1 | |
| Hydrochloric Acid SCHEMBL6279141 | 0.79 | KDM4E (0.59) | LMNAMAPTNPC1NOTUMCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227453-A1 | TRICYCLIC PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| CN-107438612-A | For treating the fused bicyclic compound of disease | 阿卡纳治疗学有限公司 | 2017-12-05 | — | — | CN | disclosed |
| CN-102863441-A | Clic central nervous system active agents | ABBOTT LAB | 2013-01-09 | — | — | CN | disclosed |
| US-7897771-B2 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-01 | — | — | US | disclosed |
| US-20110040088-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-17 | — | — | US | disclosed |
| US-20090270370-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-29 | — | — | US | disclosed |
| US-7579470-B2 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA NV (BE) | 2009-08-25 | — | — | US | disclosed |
| US-20080103132-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2008-05-01 | — | — | US | disclosed |
| EP-0488663-B1 | Pyrrolo[2,3-d]azepine derivatives, process for their preparation and pharmaceutical compositions containing them | LILLY INDUSTRIES LTD (GB) | 1997-10-08 | — | — | EP | disclosed |
| EP-0488663-A1 | Pyrrolo[2,3-d]azepine derivatives, process for their preparation and pharmaceutical compositions containing them | LILLY INDUSTRIES LIMITED (GB) | 1992-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227453-A1 | TRICYCLIC PSYCHOPLASTOGENS AND USES THEREOF | GAP43, GRIN2A, GRIN2C | LMNA 2763/4885MAPT 197/4885NPC1 421/4885 |
| US-20110040088-A1 | FUSED HETEROCYCLIC COMPOUNDS | TPH1, HTR3A, HTR3B | LMNA 4255/4885MAPT 823/4885NPC1 1180/4885 |
| US-20090270370-A1 | FUSED HETEROCYCLIC COMPOUNDS | TPH1, HTR3A, HTR3B | LMNA 4255/4885MAPT 823/4885NPC1 1180/4885 |
| US-20080103132-A1 | FUSED HETEROCYCLIC COMPOUNDS | TPH1, HTR3A, HTR3B | LMNA 4255/4885MAPT 823/4885NPC1 1180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.